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Abstract
Background Metabolic syndrome is a major risk factor
for cardiovascular diseases, which are still the major cause
of death in developed countries.
Methods We cross-sectionally studied the association
between urinary phytoestrogen excretion and metabolic
cardiovascular risk factors. Hence, we used data from the
National Health and Nutrition Examination Survey from
1999 to 2004 with 1,748 participants, who had urine levels
of isoflavones and lignans measured. Geometric means of
waist circumference, blood pressure, fasting glucose, HDL
cholesterol, and triglyceride levels were computed by
quartiles of isoflavone or lignan urinary excretion. Outcome
was assessed as the presence of metabolic syndrome
according to NCEP-ATP III criteria. The association
between phytoestrogen concentration and the metabolic
syndrome was calculated using logistic regression analyses.
Results Plasma triglyceride and HDL cholesterol levels
were lower in participants in the highest quartile of lignan
excretion compared with the lowest (both P \ 0.01).
However, blood pressure, waist circumference, and plasma
glucose levels did not differ significantly between extreme
quartiles. The presence of metabolic syndrome was lower
with increasing levels of urinary lignans (OR 0.48, 95 %
CI 0.28; 0.80 top vs. bottom quartile), especially when
separately computed for the excretion of enterolactone (OR
0.47, 95 % CI 0.28; 0.78). There was no significant asso-
ciation between isoflavone excretion and any component of
the metabolic syndrome.
Conclusions Our study shows that an increasing
excretion of lignans, especially enterolactone, might be
associated with a decreased presence of the metabolic
syndrome.
Keywords Metabolic syndrome  Phytoestrogens 
Isoflavones  Lignans  NHANES
Introduction
Over the past years, the metabolic syndrome has become a
major issue to the healthcare systems of developed coun-
tries. The worldwide prevalence of the common sequel
diabetes has increased from 153 million people in 1980 to
347 million in 2008. However, the steep increase is
alarming not only in Western countries, but also in Oceania
and South America [1]. Thus, the World Health Organi-
zation assumes that deaths from diabetes will increase by
two-thirds from 2008 to 2030 [2].
For quite some time, phytoestrogens have become an
object of interest as additional treatment option of the
metabolic syndrome [3]. Phytoestrogens are secondary
plant products and have been named because of their
structural and functional similarity to the 17b-estradiol.
They have hormonal activities by either agonistically or
antagonistically binding to the estrogen receptor and can be
divided into four groups: coumestans, lignans, isoflavones,
and stilbenes, among which isoflavones and lignans have
raised great interest as their dietary intake has been well
documented [4]. Isoflavones belong to the large class of
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flavonoids, and their main dietary components are daidz-
ein, genistein, formononetin, and biochanin A, of which
daidzein and genistein are the ones most widely studied.
They can be found in numerous vegetables, fruits, legumes,
flaxseed, and especially soybeans [5]. They are also hidden
in industrial products, i.e., baked goods, being produced
with soy flour [6]. The most abundant lignans are laric-
iresinol, pinoresinol, syringaresinol, and medioresinol. A
long time, only matairesinol and secoisolariciresinol were
investigated, and thus, lignan uptake was largely underes-
timated in Western diets. Lignans can be found in berries,
cereals, and especially flaxseed [7]. Isoflavones and lignans
are mostly consumed as glycoside and metabolized by
bacteria in the large intestine into their biologically active
forms. Although the binding capacity to the estradiol
receptors is much lower than for their endogenous coun-
terparts, it is assumed that due to the much higher serum
levels, they provide a strong biological effect in the human
body [8]. The exact ways how phytoestrogens influence the
metabolism is still unclear. On the one hand, they seem to
have a certain influence on hypothalamic neurons
decreasing food intake and increasing activity levels. On
the other hand, the activation of estrogen receptor a seems
leading to a lower adipogenesis and increases the number
of expressed glucose transporters on muscle cells [9].
It has been well documented that the amount of these
hormonally active components in a Western diet can easily
be assessed by measuring urinary concentrations [5, 10, 11].
It has not only been shown that phytoestrogens seem to
lower the risk of breast [12] and prostate [13] cancer, but in
numerous studies, it was also possible to show a beneficial
effect on cardiovascular risk factors as reviewed by Ced-
erroth [9]. Several clinical studies have been conducted to
answer the question whether phytoestrogens may improve
cardiovascular parameters. It has been reported that iso-
flavone consumption correlated with higher HDL and
lower BMI [14–16]. A Taiwanese study on postmenopausal
women comparing the effects of isoflavones and estrogens
observed a reduction in fasting glucose and insulin levels
with a daily intake of 100 mg isoflavones [17]. On the
other hand, there have also been some studies reporting no
effects of phytoestrogens on some parameters of the met-
abolic syndrome [18–20].
These favorable effects have already been taken into
account by the US Food and Drug Administration, which
issued a health claim regarding the beneficial effects of soy
proteins on coronary heart disease [21]. On the other hand,
the Natural Health Products Directorate of Health Canada
stated in August 2009 that there was not enough evidence
to support any health claims, and further research in this
field is warranted [22]. Overall, it is still unclear which
impact phytoestrogens have on cardiovascular health as
numerously reviewed. It seems as if the ability of a hosts
gut flora to convert daidzein into equol, a feature only
common to one-third of the human population, is an
important factor. Up-to-date it is not clear which bacteria
are responsible for this effect, and whether or not it can be
changed lastingly [7, 9, 23].
The objective of this study was to assess a possible
association between urinary excretion of isoflavones and
lignans, assuming that a higher excretion is associated with
a lower presence of the metabolic syndrome. The data were
derived from the National Health and Nutrition Examina-
tion Survey (NHANES) conducted between 1999 and
2004. Previously, Pen˜alvo and Lopez–Romero have
reported similar results on lipids in this survey. We
extended this analysis by looking not only at lipids but also
at other components of the metabolic syndrome [24].
Methods
Study population
All data were derived from the United States NHANES, a
cross-sectional study conducted by the Centers for Disease
Control and Prevention and under the supervision of the
National Center for Health Statistics representing the
civilian, non-institutionalized US population at least two
months old from the years 1999 to 2004. After its begin-
ning in the early 1960s, it has become a continuous pro-
gram examining a nationally representative sample of
approximately 5,000 persons per year in mobile examina-
tion centers (MEC) traveling throughout the country. To
ensure the production of reliable data with minimal sample
sizes, the study is designed to over-sample persons older
than 60 years, African Americans and Hispanics [25].
The NHANES study protocols accord with the guide-
lines laid down in the Declaration of Helsinki and were
approved by National Center for Health Statistics (NCHS)
Research Ethics Review Board (ERB), and written
informed consent was obtained from all participants [26].
Our analysis is based on the NHANES samples
1999/2000, 2001/2002, and 2003/2004. In these surveys
with a total of 31,126 participants, phytoestrogen concen-
trations in the urine were measured in one-third of the
population older than 6 years of age, leaving 7,226 [27–29].
Of these participants, we excluded all individuals
younger than 20 years of age (n = 2,985) and pregnant
women as this may interact with the possible estrogenic
effects of the phytoestrogens, leaving 4,032 individuals.
Because plasma glucose levels and serum lipid levels are
depending on nutritional intake and fasting status, we
additionally excluded participants fasting less than 8 h,
leaving 2,668 participants. Furthermore, we only included
persons from the NHANES morning sessions as triglyceride
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levels were only measured then. This left 1,748 participants
for the final analysis. We compared the distributions
(unweighted) of the above-mentioned covariates in partici-
pants of our sample with those without morning sample
weights to evaluate differences between these two groups.
General data collection
The participants were first interviewed at home with ques-
tions on sex, age, race/ethnicity, income, and education by a
standardized questionnaire, followed by an extensive phys-
ical examination including blood and urine samples at the
MEC. Sensitive habits such as alcohol and illicit drug use,
sexual behavior, smoking, and current health status were
assessed in a computer-assisted self-interview. A 24-h recall
was used to assess the dietary intake of nutrients [26].
Height, weight, and waist circumference were measured
during the examination procedure. Body mass index (BMI)
was calculated by dividing weight in kilograms by height
in meters squared. Blood pressure was measured using an
automated electronic heart rate and blood pressure monitor
from Colin (STBP-780). Urine creatinine was measured in
a Jaffe´ reaction with a CX 3 analyzer from Beckman
Coulter [30].
Urinary phytoestrogens
A spot urine sample was obtained at the MEC in collection
cups (borosilicate glass or polypropylene or standard spec-
imen cup) and was deep-frozen at -20 C right away.
Phytoestrogen concentration was measured by two different
methods. In the survey years 1999–2002, samples were
analyzed by a HPLC–APCI–MS technique as reported by
Barnes et al. [30, 31]. In the following years, the analysis
was performed at the CDC’s Division of Laboratory of
Sciences by a HPLC–electrospray ionization MS [32]. These
two methods are comparable, and they both incorporated an
enzymatic deglucoronidation before a solid-phase extraction
was conducted. Afterwards, a reverse-phase HPLC was
performed to resolve the components. A MS with internal
isotope-labeled standards was used to assure the proper
accuracy and the detection limit. A quality protocol
according to the Westgard rules was used [33].
No differences between the two different HPLC meth-
ods for urinary phytoestrogens [27, 29] were reported in the
NHANES protocols, and it has furthermore been assessed
by Pen˜alvo et al. [24], yielding no biologically reasonable
differences (NHANES 1999–2002 vs. 2003–2004).
Plasma glucose
The blood samples were drawn into sodium fluoride vials.
They were centrifugated immediately, and plasma was
frozen at -70 C. Plasma glucose was measured indirectly
in a coupled enzymatic reaction assessing the absorbance
of a by-product [30].
Serum lipids
Cholesterol blood samples were drawn into EDTA vials.
Total cholesterol was measured indirectly in a coupled
enzymatic reaction. In NHANES 1999–2000, HDL choles-
terol was assessed by a heparin–manganese precipitation
method to remove apolipoprotein B containing particles. In
NHANES 2001–2004, HDL cholesterol was assessed
directly in serum with a reagent blocking apolipoprotein B
non-reactive. Both methods during years 1999–2002 showed
undesirable bias and were adjusted according to Solomon
Park Research Laboratories (Kirkland, WA) quality con-
trols. Serum LDL levels were calculated according to the
Friedewald formula [34, 35]. Triglycerides were also mea-
sured indirectly in a coupled enzymatic reaction [34]. In
particular, triglycerides levels are influenced by diet, so we
excluded persons not fasting for at least 8 h.
Metabolic syndrome
Several proposals for a clinical diagnosis of the metabolic
syndrome have been made during the past 15 years. We
based our calculations on the revised model proposed by
the National Cholesterol Education Program—Adult
Treatment Panel III (NCEP-ATP III) from 2004 [36]
because of its clinical practicability. Furthermore, it does
not require a single predisposing cause and/or medical
condition, i.e., impaired fasting glucose or insulin resis-
tance testing, to diagnose a metabolic syndrome, but is
rather based on the simple scoring of easily assessable
clinical parameters (at least three out of five). Additionally,
this definition has been verified by a large number of
studies and has widely been accepted not only in the USA
but worldwide.
According to the NCEP-ATP III definition, these five
criteria made up the score for the metabolic syndrome:
waist circumference C102 cm in men or C88 cm in
women; systolic blood pressure C130 mmHg or use of
antihypertensives or diastolic blood pressure C85 mmHg;
plasma triglycerides C1.7 mmol/L or use of cholesterol-
lowering medication; plasma HDL cholesterol
\1.00 mmol/L (men) or \1.30 mmol/L (women); fasting
plasma glucose level C5.6 mmol/L or use of glucose-
lowering medication.
Statistical analysis
The statistical analysis was performed using STATA
software version 11.2 (College Station, Texas). Urinary
Eur J Nutr (2014) 53:1371–1381 1373
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phytoestrogen concentrations were standardized to creati-
nine concentration and expressed as lg/g creatinine. Fur-
thermore, they were computed as geometric means. The
study population was separated into quartiles of urinary
phytoestrogen concentration and weighted to take into
account over-sampling, refusal, selection probabilities, and
differences to the general US population [25] rendering
data representative. We computed means of waist cir-
cumference, systolic and diastolic blood pressure as well as
circulating levels of triglycerides, HDL, and glucose by
quartiles of urinary excretion of isoflavones and lignans.
Test for trend over quartiles was performed using the
means of creatinine-standardized phytoestrogen quartiles
as a continuous variable and performing a linear regression.
Logistic regression was used to examine the association of
urinary concentrations of isoflavones and lignans (in
quartiles) with every single dichotomized variable (yes or
no) that defines metabolic syndrome: central obesity,
hypertension, elevated triglycerides, low HDL cholesterol,
hyperglycemia, and the metabolic syndrome itself. Based
on our working hypothesis, we defined confounders and
created three logistic linear models to study the association
between the metabolic syndrome and geometric means of
urinary phytoestrogen levels. Model 1 was an unadjusted
model. Model 2 was adjusted by age, sex, race/ethnicity,
poverty income ratio (below poverty, at or above poverty
[25]), and educational level. Model 3 was furthermore
adjusted for smoking (never, former, or current), alcohol
consumption (drinks per day 0, B1, or [1), menopausal
status, use of hormone replacement therapy (HRT; yes or
no), and BMI. The analysis yielded no major differences
between the different models; hence, only results of model
3 are shown. Test for trend was conducted using the means
of the creatinine-standardized phytoestrogen quartiles as a
continuous variable and performing a logistic regression
with the desired outcome term and the new phytoestrogen
variable. All significance tests were two-sided, and
P \ 0.05 was considered to be statistically significant.
Results
In our study population, 29.1 % met the criteria of meta-
bolic syndrome. Among the participants with the metabolic
syndrome, 92.1 % had a large waist circumference, 76.4 %
had hypertension, 75.4 % had elevated triglyceride con-
centrations, 70.1 % had low HDL cholesterol concentra-
tions, and 21.7 % had elevated glucose concentrations. The
mean age of the participants was 46 years. People with a
metabolic syndrome were older than those without
(51 years, 95 % CI 50; 53 compared to 43 years, 95 % CI
42; 45). The geometric mean of total urinary excretion of
lignans was 12.9 lg/g creatinine (95 % CI 12.7; 13.0),
whereas geometric mean of total excretion of isoflavones
was 4.9 lg/g creatinine (95 % CI 4.8; 5.0) (Table 1).
Roughly, 12 % of the participants lived in poverty.
Almost 20 % had not attained a high school degree,
whereas 54 % achieved a higher education than high
school. More participants with metabolic syndrome had an
education above high school level than those without
metabolic syndrome (54.8 vs. 48.9 %). Smoking was more
common among those without metabolic syndrome
(27.1–22.2 %), whereas the proportion of former smokers
was higher among participants with metabolic syndrome
(24.7 %) than among those without the metabolic syn-
drome (23.5 %); 12.1 % of the female participants were
HRT users as defined as estrogen intake in women older
than 50 years. HRT rate was higher in women with a
metabolic syndrome (16.9 %) than in those without
(10.3 %). The mean daily intake of selected nutrients did
not differ appreciably between participants with and
without the metabolic syndrome, but it has to be taken into
account that only one 24-h dietary recall has been used to
assess a participant’s diet.
There was no statistically significant difference in sys-
tolic or diastolic blood pressure between the highest and
lowest quartiles of isoflavone excretion, but systolic blood
pressure tended to decrease with increasing lignan excre-
tion (Table 2). This corresponds with results of the logistic
regression model such that we observed no significant
association between isoflavone excretion and hypertension,
but lignans were inversely associated with hypertension
(fourth vs. first quartile: OR 0.62, 95 % CI 0.40; 0.96)
(Table 3).
There was neither a difference in plasma glucose levels
between the extreme quartiles of isoflavones nor lignan
excretion (Table 2). There was also no statistically signif-
icant association between elevated fasting glucose levels
(C5.6 mmol/L) and urinary phytoestrogens concentrations
(Table 3).
We observed a slightly, but statistically significantly
lower mean waist circumference in participants in the
lowest quartile of isoflavone excretion compared with
participants in the highest quartile (98.1 vs. 97.5 cm,
P \ 0.05), but the difference was not significant between
extreme quartiles of lignan excretion (Table 2). However,
using logistic regression analysis, there was no statistically
significant association of central obesity with isoflavone or
lignan excretion (Table 3), not even if stratified by sex
(data not shown).
There was a statistically significant difference in HDL
cholesterol concentration between the first and fourth
quartile of isoflavones (1.27 vs. 1.34 mmol/L, P \ 0.05)
and lignans (1.27 vs. 1.37 mmol/l, P \ 0.01) (Table 2). In
the multivariable logistic model (Table 3), the odds of
having low HDL cholesterol concentrations were
1374 Eur J Nutr (2014) 53:1371–1381
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Table 1 General characteristics of the study population; NHANES 1999–2004
Total
(n = 1,748)
No metabolic syndromea,b
(n = 1,239)
Metabolic syndromea,b
(n = 509)
Mean 95 % CI Mean 95 % CI Mean 95 % CI
Participants included (no.) 1,748 1,196 552
Sex, women (%) 51.4 50.2 54.9
Age (years) 45.57 44.60 46.53 43.51 42.37 44.65 51.38 49.54 53.23
Isoflavones (lg/g creatinine)c 4.85 4.76 4.95 4.88 4.76 4.99 4.79 4.62 4.96
Lignans (lg/g creatinine)d 12.85 12.74 12.95 12.95 12.82 13.07 12.57 12.38 12.77
Dietary intake of selected nutrientse
Total saturated fatty acids (gm) 27.70 26.75 28.64 27.39 26.29 28.49 28.56 26.72 30.41
Total polyunsaturated fatty acids (gm) 17.54 16.90 18.19 17.79 17.03 18.56 16.85 15.84 17.86
Dietary fiber (gm) 15.40 14.81 15.99 15.50 14.81 16.19 15.13 14.14 16.12
Total Folate (lg) 398.06 384.62 411.51 404.26 390.00 418.52 380.89 361.10 400.68
Vitamin C (mg) 86.77 80.49 93.05 87.04 79.71 94.37 86.03 75.82 96.23
Calcium (mg) 870.91 831.05 910.77 877.31 831.41 923.21 853.17 795.05 911.30
Magnesium (mg) 279.53 272.12 286.94 282.90 275.06 290.74 270.21 257.00 283.41
Race (%)
Non-Hispanic white 72.0 71.5 73.3
Non-Hispanic black 10.8 11.8 8.1
Mexican American 7.5 7.5 7.5
Other 9.7 9.2 11.0
Poverty income ratio (PIR) (%)
Below poverty 12.3 12.1 13.1
At or above poverty 81.0 81.2 80.5
Missings 6.6 6.7 6.3
Education (%)
\High school 19.8 18.6 23.2
High school 26.2 24.8 30.0
[High school 54.1 56.6 46.8
Average number of alcoholic drinks/day—past 12 months (%)
0 31.7 28.3 41.3
B1 33.1 32.8 33.8
[1 35.2 38.8 24.9
Smoking history (%)
Current smoker 25.8 27.1 22.2
Former smoker 23.8 23.5 24.7
Never 50.4 49.4 53.1
Body mass index (kg/m2) 28.4 27.9 28.8 26.9 26.5 27.2 32.7 32.0 33.4
Waist circumference (cm) 97.2 96.1 98.2 92.9 92.0 93.8 109.5 108.0 111.0
Plasma glucose (mmol/L) 5.6 5.5 5.7 5.3 5.3 5.4 6.4 6.1 6.6
Systolic blood pressure (mmHg) 122.2 121.1 123.4 119.5 118.1 121.0 129.9 128.3 131.4
Diastolic blood pressure (mmHg) 71.7 70.8 72.7 71.0 70.0 72.0 73.9 72.4 75.3
HDL cholesterol (mmol/L) 1.32 1.30 1.35 1.41 1.38 1.43 1.10 1.07 1.13
Triglycerides (mmol/L) 1.71 1.57 1.85 1.36 1.24 1.48 2.69 2.40 2.98
Use of HRT in women (%) 12.1 10.3 16.9
Exclusion due to limited data of phytoestrogen levels: participants younger than 20 years old, pregnancy, fasting less then 8 h
a Metabolic syndrome: one point for each of the following: systolic blood pressure C130 mmHg or use of antihypertensives or diastolic blood pressure
C85 mmHg; plasma triglycerides C1.7 mmol/L or use of cholesterol-lowering medication; plasma HDL cholesterol\1.00 mmol/L (men) or\1.30 mmol/L
(women); waist circumference[102 cm (men) or[88 cm (women); plasma glucose level C5.6 mmol/L or use of glucose-lowering medication; range 0–5
points, diagnosis of metabolic syndrome met with C3 points
b Values are adjusted for age, race/ethnicity, education, income, smoking, alcohol categories, BMI
c Geometric mean in lg/g creatinine: daidzein, equol, genistein, o-demethylangolesin
d Geometric mean in lg/g creatinine: enterodiol, enterolactone
e From 24-h recalls
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significantly lower in participants with highest levels of
isoflavone (OR 0.65, 95 % CI 0.46; 0.92) and lignan (OR
0.64, 95 % CI 0.41; 0.99) excretion compared with lowest
levels.
Circulating levels of triacylglycerols differed between
extreme quartiles of isoflavones (first quartile 2.09 vs.
fourth quartile 1.56 mmol/L, P \ 0.05) and lignan excre-
tion (2.04 vs. 1.46 mmol/L, P \ 0.001) (Table 2). There
was no statistically significant association between iso-
flavone excretion and having elevated triglyceride con-
centration (Table 3), but lignan excretion was statistically
significantly inversely associated with the odds of having
elevated triglyceride concentration (fourth vs. first quartile:
OR 0.39, 95 % CI 0.28; 0.56).
In the multivariable logistic model (Table 3), only high
urinary lignan concentrations were related to decreased
odds of metabolic syndrome (top vs. bottom quartile: OR
0.48, 95 % CI 0.28; 0.80). To further differentiate the
responsible agent, we computed values for enterodiol and
enterolactone separately and observed a statistically sig-
nificantly inverse association between enterolactone
excretion and odds of metabolic syndrome (OR 0.47, 95 %
CI 0.28; 0.78), but not for enterodiol excretion (OR 0.73,
95 % CI 0.44; 1.20). The test for heterogeneity between the
two lignans was not statistically significant (P [ 0.05). We
also computed the results adjusted for the dietary nutrients
shown in Table 1. There were no appreciable differences.
We further compared the means of waist circumference,
blood pressure, glucose, and HDL levels of our sample
(morning sessions) with the means of the non-included
participants from the afternoon sessions (n = 920), yield-
ing no particular difference. Just the levels of urinary
lignans and isoflavones were roughly 100 lg/g creatinine
lower in the afternoon sessions.
Discussion
In this cross-sectional study of the general US population,
we observed a statistically significant association between
urinary excretion of lignans and the metabolic syndrome,
such that participants with high excretion of these lignans,
in particular enterolactone, had lower odds of having the
metabolic syndrome compared with participants with low
lignan concentrations. When looking at single components
of the metabolic syndrome, an increase in HDL cholesterol
over quartiles of both isoflavones and lignans was observed
as well as a decrease in triglyceride concentration and a
lower waist circumference.
To the best of our knowledge, we conducted the first
study on urinary phytoestrogen excretion and their effects
on all parameters of the metabolic syndrome. So far, most
studies only examined single components of the metabolicT
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syndrome or used dietary questionnaires [37] to estimate
phytoestrogen intake. There is only one randomized con-
trolled study [38] using lignans, which showed a slight
decrease in diastolic blood pressure and triacylglycerol
only in men. Additionally, we included both men and
women, whereas most previous research has only been
conducted among women [15, 39, 40].
NHANES has only one 24-h dietary recall, and it is
known that the elimination half-life of phytoestrogens
ranges from 7 to 36 h, depending on the actual component
[41–44]. This has led to concerns whether urinary excretion
concentrations were valid biomarkers of dietary phytoes-
trogen intake, especially as these nutrients are to be con-
sumed only on an irregular basis in Western societies [6].
To assure its reliability, several studies have been con-
ducted with spot urine [5, 10, 11, 45], stating that mea-
suring spot urinary phytoestrogen concentrations is a valid
approach for estimating dietary phytoestrogen exposure.
One must be aware that the interpretation of our results
is limited by the cross-sectional design, not allowing for
the differentiation between cause and effect. To test whe-
ther phytoestrogen consumption affects the risk of meta-
bolic syndrome, longitudinal studies with preferably
multiple measurements would better reflect actual disease
status (e.g., levels of glucose and cholesterol) and phyto-
estrogen levels. Although NHANES offers a large popu-
lation sample reducing the chance for selection bias, only a
subsample of one-third of the participants were tested for
urinary phytoestrogens, thus, reducing sample size. How-
ever, large samples would be needed to detect statistically
significant differences as large reviews of several studies
[7, 9, 46, 47] showed only small effects of phytoestrogens
in human populations. For example, a meta-analysis found
a mean reduction of only 0.10 mmol/L of LDL cholesterol
over all studies. HDL and triglyceride levels did not differ
significantly after a lignan supplementation [48]. Hence, a
Table 3 Multivariable logistic association between quartiles of phytoestrogen concentration and parameters of metabolic syndrome; participants
aged C20 years old, NHANES 1999–2004
Quartiles of phytoestrogen concentrationa Test for trend
1 2 3 4
Odds ratio Odds ratio 95 % CI Odds ratio 95 % CI Odds ratio 95 % CI P value
Hypertension
Isoflavonesb 1.00 0.83 0.51–1.36 0.82 0.55–1.20 0.87 0.56–1.36 0.58
Lignansc 1.00 0.81 0.54–1.22 0.73 0.48–1.09 0.62 0.40–0.96 0.045
Plasma glucose level
Isoflavonesb 1.00 0.73 0.31–1.71 1.36 0.62–2.95 1.09 0.62–2.95 0.45
Lignansc 1.00 1.84 0.89–3.80 1.01 0.37–2.80 1.98 0.79–4.95 0.56
Waist circumference
Isoflavonesb 1.00 0.99 0.58–1.69 1.33 0.57–3.13 0.90 0.48–1.67 0.99
Lignansc 1.00 0.61 0.28–1.33 0.52 0.28–0.96 0.86 0.42–1.76 0.61
HDL
Isoflavonesb 1.00 0.87 0.57–1.32 0.89 0.54–1.43 0.65 0.46–0.92 0.03
Lignansc 1.00 0.73 0.52–1.03 0.59 0.39–0.89 0.64 0.41–0.99 0.06
Triglycerides
Isoflavonesb 1.00 0.84 0.58–1.21 0.97 0.66–1.42 0.77 0.54–1.11 0.20
Lignansc 1.00 0.66 0.41–1.05 0.46 0.33–0.65 0.39 0.28–0.56 \0.001
Metabolic syndromed
Isoflavonesb 1.00 1.04 0.69–1.56 1.00 0.62–1.61 0.81 0.55–1.18 0.24
Lignansc 1.00 0.67 0.45–1.00 0.57 0.37–0.86 0.48 0.28–0.80 0.02
Enterodiol 1.00 0.75 0.47–1.18 0.70 0.45–1.10 0.73 0.45–1.20 0.12
Enterolactone 1.00 0.60 0.40–0.89 0.58 0.38–0.86 0.47 0.28–0.78 0.003
Values are adjusted for age, sex, race/ethnicity, education, income, smoking, alcohol categories, BMI, menopause status, and HRT
a Geometric mean in lg/g creatinine
b Daidzein, equol, genistein, o-demethylangolesin
c Enterodiol, enterolactone
d According to NCEP-ATP III definition: waist circumference C102 cm (men) or C88 cm (women); systolic BP C130 or diastolic
BP C85 mmHg or use of medication; triglycerides C1.7 mmol/L or use of medication; HDL \1.00 mmol/L (men) or\1.30 mmol/L (women);
glucose C5.6 mmol/L or use of medication
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large randomized controlled trial would be necessary to
draw a final conclusion. Persons prone to developing a
metabolic syndrome might also be missed. This issue
should best be addressed by a cohort study. Furthermore,
we did not asses the excretion of other phytoestrogens such
as stilbenes or coumestans. Although their actual impact on
cardiovascular disease is not clear [7], they may have
influenced our results.
Although we adjusted our results for potential differ-
ences in income/wealth of the study population and edu-
cational level, we did not see a difference between these
models (models 1 and 2). This might be due to rather basic
poverty income ratio and educational levels used by
NHANES. A more elaborate data set on this issue would
help to further delineate the social classes and their actual
dietary habits and lifestyle. Consequently, we cannot
exclude that richer households are the ones that not only
lead a healthier lifestyle [49] but also are the ones con-
suming more vegetable products and having subsequently a
higher phytoestrogen intake [50, 51]. Although we made
adjustments for smoking status, it could be possible that
former smokers changed their lifestyle vigorously after
cessation, leading to an overall healthier life compared
with never smokers.
It is well known that Asians have a higher intake of soy
food than found in Western societies. So far, NHANES
does not over-sample Americans of Asian descent [52],
which is not going to be integrated until the 2011 surveys.
This would warrant further studies as it is known that the
amount of excreted metabolites varies greatly even among
different Asian populations, although their diets lead to a
higher consumption of phytoestrogenic nutrients, in par-
ticular isoflavones [53, 54]. Their possible increased con-
sumption of soy products may lead to significant effects of
isoflavones on the parameters we have observed. Based on
the current NHANES data, we do not know of a compre-
hensive comparison of these three populations. In general,
urinary levels of isoflavones of our sample were lower than
those measured in Vietnamese and Japanese samples,
whereas levels of lignans of our sample were higher
compared to the samples of the Asian study [45]. However,
the comparison between different studies is difficult
because many different assessment methods are being used
(e.g., study design, units, and measurements) making
interpretation difficult. A future analysis of the NHANES
2011–2014 might reveal interesting insights, especially if
the dietary intake of phytoestrogens in the Asian popula-
tion is compared with the Caucasian. So far, a conclusive
statement cannot be made.
Elevated plasma glucose concentrations are the hallmark
of a beginning insulin resistance or the sign of a manifest
type 2 diabetes mellitus leading to manifold complications,
e.g., cardiovascular disease, diabetic retinopathy, or
polyneuropathy [55]. It is commonly assumed that this
underlying insulin resistance is a basic etiologic cause
leading to the manifestation of the metabolic syndrome
[56]. Several experimental trials with rodents have shown
that the administration of phytoestrogens increases excre-
tion of insulin by pancreatic b-cells and decreases periph-
eral insulin resistance by increasing glucose uptake in
skeletal muscles [57–59]. There are also trials in humans
presenting similar effects [17, 60, 61]. In contrast to these
results, we could not detect any association of phytoes-
trogens excretion on plasma glucose levels in our analysis.
We speculate this could be due to the small biological
impact of phytoestrogens as consumed in a habitual diet, as
already observed by others [20, 62].
Participants with high isoflavone or lignan excretion had
lower waist circumference compared with those with low
phytoestrogen excretion. However, there was no associa-
tion between phytoestrogen excretion and risk of being
centrally obese. Although several studies showed promis-
ing results on this topic [14, 19, 37, 63], there are contra-
dictory results, too [15, 18, 38]. To the best of our
knowledge, there is no comprehensive meta-analysis up-to-
date.
There are several studies showing no effects of phy-
toestrogens on blood pressure as reviewed by Rosero et al.
[64]. There is also increasing evidence that HRT in post-
menopausal women is not able to lower blood pressure
[65], which further supports this conclusion, as phytoes-
trogens are supposed to induce a similar state in post-
menopausal women. In our study, we observed lower odds
of hypertension among participants with high lignan
excretion, but mean blood pressure values did not differ by
quartiles of lignan excretion. Thus, taking the results of
previous studies into account, we speculate that our
observation in the logistic regression model might be due
to residual confounding as mentioned above.
As previously published by Pen˜alvo and colleagues for
the same set of data [24], we also observed a positive
association between HDL cholesterol concentration and
excretion of lignans and isoflavones. These effects are
contradictory to two extensive meta-analyses of random-
ized controlled trials [48, 66], which reported no effects of
flaxseed and lignan supplements or soy proteins, respec-
tively, on HDL cholesterol concentrations. We also
observed a significant decrease in triglyceride concentra-
tion with increasing levels of lignan excretion; an effect
already observed by Pen˜alvo et al. [24]. This, however, is
not consistent with the meta-analyses mentioned earlier
[48], which did not show any statistically significant effects
of lignans on triglyceride levels. To the best of our
knowledge, there are no further data concerning this issue,
and the differences found might be attributed to chance.
Clinically, increases in HDL cholesterol are considered to
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be more important because low HDL cholesterol is seen as
major risk factor in atherosclerosis besides high levels of
LDL cholesterol and triglycerides [67]. This HDL
increasing association might even have clinical impact as
most medications against dyslipidemia, except niacin,
decrease LDL cholesterol and triglyceride concentrations
but only increase HDL cholesterol slightly [67]. Other
interventions such as HRT have shown to increase HDL
cholesterol [68] but do have side effects that are not desired
in a public being widely interested in alternative medical
treatment [69].
Many authors consider the metabolic syndrome an
accumulation of potent cardiovascular risk factors. Whe-
ther insulin resistance or obesity is the underlying cause of
the metabolic syndrome is still a subject of debate [56].
Nevertheless, manifestation of diabetes mellitus type 2
increases the risk of cardiovascular diseases dramatically.
At the end, these multiple risk factors have a much higher
influence on cardiovascular disease than a single factor
would have. There was no association between isoflavone
excretion and presence of a metabolic syndrome in our
study population, in contrast to de Kleijn and colleagues
[37]. On the other hand, we observed statistically signifi-
cant lower odds of metabolic syndrome with increasing
amounts of urinary lignans, as already observed by others,
too [37, 38]. To further analyze this effect, we computed
results for both enterodiol and enterolactone, of which only
enterolactone had a statistically significant impact. We
assume this effect is mostly due to the beneficial effects of
lignans on triglycerides and on HDL.
In summary, our study on the metabolic syndrome and
its relation to the urinary excretion of phytoestrogens
shows that a higher excretion of lignans, especially en-
terolactone, might be associated with the metabolic syn-
drome, such that we conclude that a high consumption of
foods rich in lignans may protect from this complex of
diseases—an association that has only been shown previ-
ously by de Kleijn, but for dietary-assessed phytoestrogens
instead of urinary excretion [37]. This might be due to a
healthier lifestyle but has been taken into account by
adjusting for these confounders. However, further studies
are needed to confirm our cross-sectional observation.
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